How should an adult with documented gastro‑oesophageal reflux disease who is stable on pantoprazole and has no contraindications to vonoprazan be transitioned to vonoprazan (voquezna)?

Transitioning from Pantoprazole to Vonoprazan in GERD Patients

Direct Transition Strategy

For stable GERD patients on pantoprazole, simply stop pantoprazole and start vonoprazan the next day at the appropriate dose based on disease severity—no tapering or washout period is required. 1

Dosing Algorithm Based on GERD Severity

For Erosive Esophagitis (Los Angeles Grades C/D)

• Start vonoprazan 20 mg once daily for 8 weeks to achieve healing 1
• After healing is confirmed, reduce to vonoprazan 10 mg once daily for maintenance (up to 6 months) 1
• Vonoprazan demonstrates superior maintenance of healing compared to continuing pantoprazole, with recurrence rates of 5-13% versus 39% 2

For Mild Erosive Esophagitis (Los Angeles Grades A/B) or Non-Erosive GERD

• Do not transition to vonoprazan—continue pantoprazole 2
• Vonoprazan offers no clinical advantage over standard PPIs for mild disease and costs substantially more 2
• If symptoms persist on pantoprazole 40 mg once daily, increase to pantoprazole 40 mg twice daily before considering vonoprazan 2

For PPI-Resistant GERD

• Only transition after documented failure of pantoprazole 40 mg twice daily 2, 3
• Start vonoprazan 20 mg once daily, which achieves 91.7% healing rates at 4 weeks in PPI-resistant erosive esophagitis 3
• For PPI-resistant non-erosive GERD, vonoprazan improves symptoms in 74.6% of patients at 4 weeks 3

Timing and Administration

• Vonoprazan can be taken with or without food, unlike pantoprazole which should be taken 30-60 minutes before meals 1
• This pharmacologic advantage stems from vonoprazan's acid stability—it does not require conversion to an active form and provides immediate action 2
• No overlap period is needed; the transition can occur immediately because vonoprazan's mechanism (potassium-competitive acid blockade) is independent of the PPI mechanism 4

Dose Adjustments for Special Populations

Renal Impairment

• eGFR ≥30 mL/min: Use standard dosing (20 mg for healing, 10 mg for maintenance) 1
• eGFR <30 mL/min: Reduce healing dose to 10 mg once daily; maintenance dose remains 10 mg once daily 1

Hepatic Impairment

• Child-Pugh A: Use standard dosing (20 mg for healing, 10 mg for maintenance) 2, 1
• Child-Pugh B or C: Reduce healing dose to 10 mg once daily; maintenance dose remains 10 mg once daily 1

Critical Pitfalls to Avoid

• Do not transition patients with mild GERD or those well-controlled on pantoprazole—vonoprazan is substantially more expensive and offers no clinical benefit in these populations 2
• Do not assume vonoprazan is automatically superior—for most GERD patients, pantoprazole 40 mg once or twice daily remains first-line therapy 2
• Do not skip the trial of double-dose PPI therapy (pantoprazole 40 mg twice daily) before escalating to vonoprazan in refractory cases 2
• Do not forget to test for H. pylori in patients with persistent symptoms, as vonoprazan-based eradication regimens achieve 92% success versus 80% with PPI-based therapy 2, 5

Monitoring After Transition

• Assess symptom response at 4 weeks for erosive esophagitis patients 3
• Confirm healing with endoscopy at 8 weeks if severe erosive esophagitis (LA grades C/D) was documented initially 2
• Monitor for adverse events including abdominal pain, constipation, diarrhea, nausea, and dyspepsia, though vonoprazan is generally well-tolerated with safety comparable to PPIs 4, 3
• Check serum gastrin levels if long-term therapy is planned, as vonoprazan raises gastrin 2-3-fold higher than PPIs, though levels normalize within weeks after discontinuation 2

When Vonoprazan Is NOT Appropriate

• First-line therapy for any GERD severity—pantoprazole and other PPIs remain preferred initial agents 2
• Patients stable on current pantoprazole regimen—no evidence supports switching for cost or convenience 2
• Mild symptoms or uncomplicated GERD—the higher cost cannot be justified when pantoprazole is equally effective 2